Crescent Biopharma CBIO
NASDAQ CBIO
$14.65 +0.73 (+5.28%)
As of: Nov 11, 2026 · 3:30 PM EST

Crescent Biopharma (CBIO) Change in Intangibles (2026)

Updated

Crescent Biopharma (CBIO) recorded Change in Intangibles of $8 million in Q1 2026.

Analysis

Crescent Biopharma (CBIO) Change in Intangibles (2026) Analysis & Trends

For FY2025, Crescent Biopharma reported Change in Intangibles of $72 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Intangibless (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.06 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 995.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -7.20 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Crescent Biopharma 386.36 Mn -320.93 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 8.00 Mn
API Access

Crescent Biopharma Change in Intangibles API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-intangibles&ticker=CBIO&period=max&api_key=YOUR_API_KEY